View Older Stories View More Recent Stories

May 15, 2017 08:00AM Advaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac
May 5, 2017 10:00AM Erin Andrews to Participate in Cervical Cancer Educational Forum Hosted by Sylvester Comprehensive Cancer Center and Gilda’s Club, Sponsored by Advaxis
Apr 27, 2017 08:00AM Advaxis Recognized as One of New Jersey’s “Best Places to Work 2017”
Apr 19, 2017 08:00AM Advaxis Appoints Anthony Lombardo as Chief Business Officer
Mar 27, 2017 08:00AM Advaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac
Mar 23, 2017 08:00AM EMA Certification Paves the Way for the MAA Submission for Axalimogene Filolisbac in Metastatic Cervical Cancer
Mar 15, 2017 07:09AM Advaxis (ADXS) Presents Oral Late-breaking Data on Phase 2 GOG-0265 Study of Axalimogene Filolisbac at SGO Meeting
Mar 15, 2017 07:00AM Advaxis Presents Oral Late-breaking Data on Phase 2 GOG-0265 Study of Axalimogene Filolisbac at SGO’s Annual Meeting on Women’s Cancer
Mar 13, 2017 08:00AM Advaxis to Present at the 2017 Barclays Global Healthcare Conference
Mar 7, 2017 08:00AM Advaxis Appoints Al Blunt, M.D., as its Vice President of Medical
Mar 6, 2017 06:02AM Advaxis (ADXS) IND for ADXS-NEO Accepted by FDA
Mar 6, 2017 06:00AM Advaxis Announces FDA Acceptance of IND for Groundbreaking Personalized Neoepitope Immunotherapy, ADXS-NEO
Mar 2, 2017 08:00AM Advaxis to Host Research Reception at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer
Feb 27, 2017 08:02AM Advaxis (ADXS), SELLAS Enter Licensing Agreement for Development of WT1 Antigen-Targeting Immunotherapy
Feb 27, 2017 08:00AM Advaxis and SELLAS Announce Licensing Agreement for Development of WT1 Antigen-Targeting Immunotherapy
Feb 27, 2017 08:00AM Advaxis and SELLAS Announce Licensing Agreement for Development of WT1 Antigen-Targeting Immunotherapy
Feb 6, 2017 08:06AM Advaxis (ADXS) Doses First Patient in Phase 3 AIM2CERV Trial
Feb 6, 2017 08:00AM Advaxis Announces First Patient Dosed in Global Phase 3 AIM2CERV Trial for High-risk, Locally Advanced Cervical Cancer
Jan 30, 2017 08:30AM GOG-0265 Study in Metastatic Cervical Cancer Selected for Late-Breaking Data Presentation at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer
Jan 25, 2017 08:00AM New Published Research Reveals that Cervical Cancer Mortality Rates May Be Significantly Higher in the United States than Previously Reported
Jan 9, 2017 08:00AM Advaxis Provides 2017 Business Outlook
Dec 12, 2016 08:17AM Advaxis' (ADXS) Lm Technology Focus at International Congress on Immunotherapies in Cancer
Dec 12, 2016 08:15AM Discussion on Advaxis’ ADXS-NEO, ADXS-HOT Programs Held During the International Congress on Immunotherapies in Cancer
Dec 7, 2016 08:00AM Advaxis to Present Data at ImVacS-Immunization and Vaccine Summit on Use of Detoxified Listeriolysin O (dtLLO) as an Effective Adjuvant in Vaccine Formulations
Nov 15, 2016 08:00AM Advaxis to Present at the Jefferies 2016 London Healthcare Conference
Nov 11, 2016 07:30AM Advaxis to Present Phase 1 Combination Data and New Preclinical Data Using AXAL at Upcoming Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting
Oct 24, 2016 08:02AM Advaxis (ADXS) Announces Topline Data from Phase 2 GOG-0265 Stage 2; OS Data Consistent with Prior Results
Oct 24, 2016 08:00AM Advaxis Announces GOG-0265 12-month Overall Survival Rate of 37.5% in Stage 2
Oct 20, 2016 07:32AM Advaxis (ADXS) Commences KEYNOTE-046 Phase B with Merck (MRK)
Oct 20, 2016 07:30AM Advaxis Initiates Combination Portion of Phase 1/2 Study with Merck
Oct 14, 2016 08:30AM Cancer Immunotherapy ETF Celebrates One-Year Anniversary
Oct 13, 2016 08:10AM Advaxis (ADXS) Approved for $2.7M NJEDA NOL Program Tax Credit
Oct 13, 2016 08:00AM Advaxis to Receive $2.5M through the New Jersey Economic Development Authority NOL Program
Oct 11, 2016 08:00AM Advaxis Research Reception at SITC 2016 to Review Recent AXAL Highlights and the AXAL-Durvalumab Combination Poster
Oct 6, 2016 08:00AM Advaxis CSO Invited to Speak at Immune Profiling World Congress
Oct 3, 2016 08:02AM Advaxis (ADXS) Names New COO
Oct 3, 2016 08:00AM Advaxis Appoints Christopher Duke as Chief Operating Officer
Sep 26, 2016 03:45PM Advaxis’ Lm Technology Immunotherapies to be Showcased in Three Poster Presentations at SITC Annual Meeting
Sep 19, 2016 04:30PM Advaxis to Present at the Aegis Annual Growth Conference
Sep 12, 2016 08:00AM Advaxis Unveils State-of-the-art Manufacturing Facility, Laboratory to Produce and Develop Novel Immuno-Oncology Therapeutics
Sep 8, 2016 02:28PM N.J. Gov. Christie to Attend Advaxis Ribbon Cutting for New Manufacturing/Laboratory Facility in Princeton
Aug 11, 2016 08:03AM Advaxis (ADXS) Says AXAL Met Phase 1 Primary Objective; Will Advance to Phase 2
Aug 11, 2016 08:00AM Advaxis Announces that Phase 2 Head and Neck Cancer Study with AXAL Advances to Second Stage
Aug 2, 2016 08:02AM Amgen (AMGN), Advaxis (ADXS) Enter ADXS-NEO Global Development, Commercialization Agreement
Aug 2, 2016 08:00AM Amgen And Advaxis Enter Global Cancer Immunotherapies Collaboration
Jul 26, 2016 08:00AM Phase 1/2 Combination Trial of AXAL and Durvalumab Completes Second Dose-Escalation Cohort
Jul 21, 2016 07:02AM Advaxis (ADXS) Granted FDA Fast Track Designation for AXAL
Jul 21, 2016 07:00AM Advaxis’ AXAL Receives Fast Track Designation by the FDA as Adjuvant Therapy for High-Risk Locally Advanced Cervical Cancer Patients
Jul 18, 2016 07:31AM Advaxis' (ADXS) AXAL Receives EMA ATMP Classification as Cervical Cancer Treatment
Jul 18, 2016 07:30AM European Medicines Agency Committee Classifies Advaxis’ Axalimogene Filolisbac as an Advanced-Therapy Medicinal Product
View More Recent Stories View Older Stories